Transthyretin mRNA · NUCLEIC-ACID · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Transthyretin mRNA shows approved-linked disease relevance led by familial amyloid neuropathy. 4 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt ENSG00000118271. Start with familial amyloid neuropathy, then reuse UniProt ENSG00000118271 as the stable protein anchor across project notes and exports.
Start with familial amyloid neuropathy, then reuse UniProt ENSG00000118271 as the stable protein anchor across project notes and exports.
Transthyretin mRNA shows approved-linked disease relevance led by familial amyloid neuropathy. 4 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.
Start review with familial amyloid neuropathy because it currently carries approved-linked support. Linked drugs include EPLONTERSEN, EPLONTERSEN SODIUM, INOTERSEN, INOTERSEN SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTransthyretin mRNA
Review this target as Transthyretin mRNA, mapped to UniProt ENSG00000118271.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Transthyretin mRNA as ChEMBL target CHEMBL4296221, mapped to UniProt ENSG00000118271. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Transthyretin mRNA is the right protein anchor across sources, using UniProt ENSG00000118271 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why familial amyloid neuropathy is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Transthyretin mRNA |
| Target Type | NUCLEIC-ACID |
| Organism | Homo sapiens |
| UniProt | ENSG00000118271 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Transthyretin mRNA |
| UniProt Accession | ENSG00000118271 |
| Component Type | Rna |
Transthyretin mRNA
Review this target as Transthyretin mRNA, mapped to UniProt ENSG00000118271.
Open Targets-ready disease context using the current target-indication evidence contract.
Transthyretin mRNA shows approved-linked disease relevance led by familial amyloid neuropathy. 4 more disease programs remain visible in the same review block.
Start review with familial amyloid neuropathy because it currently carries approved-linked support. Linked drugs include EPLONTERSEN, EPLONTERSEN SODIUM, INOTERSEN, INOTERSEN SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.